PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) —
ERASCA, INC. (NASDAQ: ERAS):
Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.
What is This Investigation About? The investigation concerns whether Erasca’s directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company’s public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.
If you are a current Erasca (NASDAQ: ERAS) shareholder who has held shares since prior to January 14, 2025, you seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/erasca-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085.
What is Alleged? According to a recently filed federal securities class action Erasca, Inc. (NASDAQ: ERAS), through certain of its officers, made materially misleading statements and omissions concerning ERAS-0015. Among other things, the underlying class action complaint alleges that: Erasca publicly promoted ERAS-0015 as a potential “best-in-class” therapy and made repeated comparisons between ERAS-0015 and Revolution Medicines’ RMC-6236; the Company’s public disclosures allegedly relied upon improper comparisons to RMC-6236; Erasca allegedly faced intellectual property, patent, and trade-secret-related risks associated with those comparisons and related disclosures; investors allegedly were not adequately informed of those risks; and certain positive statements regarding ERAS-0015 allegedly lacked a reasonable basis when made.
April 2026 Disclosures: On April 27, 2026, Erasca disclosed that it had received correspondence from counsel for Revolution Medicines alleging, among other things, patent infringement, trade-secret-related issues, and allegedly improper comparative statements concerning ERAS-0015 and RMC-6236. Later that same day, Erasca disclosed preliminary Phase 1 clinical data regarding ERAS-0015 and reported that one patient who received ERAS-0015 had died after experiencing pneumonitis that progressed following withdrawal of supportive care. The Company also disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses rather than head-to-head clinical trials and that such comparisons were inherently limited. Following these disclosures, Erasca’s share price experienced a substantial decline.
What Can You Do Now? If you are a current Erasca, Inc. (NASDAQ: ERAS) shareholder and have held shares since prior to January 14, 2025, you can seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/erasca-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. #Erasca #ERAS $ERAS
Hub Group, Inc. (NASDAQ: HUBG):
Grabar Law Office is investigating claims on behalf of shareholders of Hub Group, Inc. (NASDAQ: HUBG).
What Is This Investigation About? The investigation concerns whether certain officers and directors of Hub Group, Inc. breached the fiduciary duties they owed to the company.
If you purchased Hub Group, Inc. (NASDAQ: HUBG), shares prior to April 28, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/hubg-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
What is Alleged? As alleged in a recently filed securities fraud class action complaint, Hub Group, Inc. (NASDAQ: HUBG), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Hub Group’s financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements caused by the premature and incorrect recognition of certain transactions concerning, among other things, Hub Group’s operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth; and (2) Hub Group’s financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements caused by the understatement of purchased transportation costs and accounts payable concerning, among other things, Hub Group’s operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth.
What Can You Do Now? If you purchased Hub Group, Inc. (NASDAQ: HUBG), shares prior to April 28, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/hubg-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #HUBG #HubGroup #HUBG
Hyliion Holdings Corp. (NYSE: HYLN):
Grabar Law Office is investigating potential claims on behalf of shareholders of Hyliion Holdings Corp. (NYSE: HYLN).
What is This Investigation About? The investigation concerns whether certain Hyliion officers and directors breached the fiduciary duties they owed to the Company as it pertains to Hyliion’s Disclosures Regarding Its VFG Holdings Partnership and Alleged Insider Stock Sales.
If you purchased Hyliion Holdings Corp. (NYSE: HYLN) shares prior to May 12, 2026 and still hold shares today, visit https://grabarlaw.com/the-latest/hyliion-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at (267) 507-6085. You can seek corporate governance reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
What is Alleged? On August 28, 2026, a federal securities fraud class action complaint was filed against Hyliion and certain of its officers in the United States District Court for the Western District of Texas. According to the complaint, Hyliion announced on May 12, 2026 that it had entered into a non-binding letter of intent with VFG Holdings, LLC (“VFG”) establishing what the Company described as a strategic partnership involving the potential deployment of KARNO Power Modules for data-center applications. Hyliion stated that the parties intended to pursue opportunities involving as many as 250 KARNO Cores, representing approximately 50 megawatts of power-generation capacity, over a five-year period.
The underlying class action complaint alleges that Hyliion materially overstated the prospects and significance of the VFG relationship. Among other things, the complaint alleges that VFG had only been formed in January 2026, appeared to have approximately four employees, maintained a website containing limited information, and appeared to have publicized no meaningful business activity apart from its announced relationship with Hyliion.
The complaint further alleges that Hyliion officers sold Company shares shortly after the VFG announcement pursuant to Rule 10b5-1 trading plans. The cited transactions include the reported sale of 30,000 shares by Chief Executive Officer Thomas Healy for approximately $125,000 and 15,000 shares by Chief Financial Officer Jon Panzer for approximately $61,000.
On June 23, 2026, Pelican Way Research published a report questioning the substance of the proposed VFG transaction and VFG’s apparent ability to carry it out. According to the complaint, Hyliion’s stock price declined approximately 17.2% on June 23, 2026 and an additional 19.3% on June 24, 2026.
What Can You Do Now? If you acquired Hyliion Holdings Corp. (NYSE: HYLN) shares before May 12, 2026, and still own Hyliion stock today, you are encouraged to visit https://grabarlaw.com/the-latest/hyliion-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com or call (267) 507-6085. You can seek corporate-governance reforms, the return of funds to the Company, and, a court approved incentive award—all at no cost to you whatsoever. #Hyliion #HYLN $HYLN
PROCEPT BioRobotics Corporation (NASDAQ: PRCT):
Grabar Law Office is investigating claims on behalf of shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT).
What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares before February 28, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/procept-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
What is Alleged? As alleged in a recently filed securities fraud class action PROCEPT BioRobotics Corporation (NASDAQ: PRCT), through certain of its officers, made materially false and misleading statements and/or failed to disclose materially adverse facts including: (i) that Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated Procept’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of (i)-(iv) above, defendants’ representations regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of (i)-(v) above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of (i)-(vi) above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.
What Can You Do Now? If you purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares before February 28, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/procept-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Procept #PRCT $PRCT
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
